A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome LIBREXIA-ACS
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
Study ID: 3270
NCT Number: NCT05754957
Principal Investigator: Albert Chan, MD
Department: Medicine-Cardiology
Eligibility: Both men and women 18 years old to 100 years old. Does not accept healthy volunteers.
For questions about this study, please contact:
ClinicalTrialsInterest@health.missouri.edu(573) 882-7026